Volume momentum & margin recovery on the watch for Q2
Eureka Forbes reports Q2 FY27 on November 2. The Street expects sustained revenue growth, but margin recovery from Q1's 10.5% EBITDA dip and execution on water purifier penetration (7% household adoption) will be the real test.
For Eureka Forbes, the earnings print will hinge on three threads: whether volume growth (the 15.3% YoY revenue jump in Q1) carries into Q2, whether EBITDA margins normalize back toward FY26's 12.2% after Q1's 10.5% dip, and whether the company is penetrating the water purifier opportunity (7% household adoption) at the cadence investors have priced in. Everything else—GST relief, ESG ratings, pledges—is noise if execution on these three stays on track.
What to expect: the on-plan grid
~₹700-750 Cr
Q1 was ₹700 Cr (+15.3% YoY); Q2 seasonal run-rate suggests mid-to-high end of range
~12%
Q1 slipped to 10.5% (vs FY26 FY 12.2%); street expects Q2 to normalize as spends stabilize
~₹45-50 Cr
Q1 PAT ₹57 Cr included ₹19.5 Cr gratuity one-off; Q2 likely normalized run-rate
~43%
Electric purifier segment was 42.8% of mix in FY26; on-plan for Q2
A strong print: Revenue ₹750+ Cr with EBITDA margin at or above 12%, signaling both volume momentum and margin discipline. Electric water purifier growth accelerating ahead of the 7% penetration floor, with commentary on emerging markets (small appliances, robotics) holding up. PAT normalized at ₹48-50 Cr. A weak print: Revenue flatlining near ₹680 Cr or lower (momentum stalls vs Q1). EBITDA margin stays below 11%, suggesting cost pressures or promotional intensity weighing harder. Water purifier mix declining as a % of overall revenue. Any fresh regulatory surprises.
On track for the year?
Eureka Forbes guided for meaningful acceleration from FY27 onwards, with revenue doubling to ₹5,400–5,600 Cr and EBITDA tripling to ₹800–850 Cr by FY30. Q1 delivered on the volume front (15.3% YoY), but Q1 margins disappointed (10.5% vs FY26's 12.2%). For the company to hit its mid-term targets, it needs to prove FY27 can grow top-line and recover operating leverage—not one or the other. Q2 is the first real test of that thesis. If margins stay compressed, the market will reprrice the FY30 feasibility, especially given the stock is already down 54% from its ₹668 high.
What the Street says
Since last quarter: the filings read
1 · GST liability relief: ₹273 Cr show cause → ₹4.5 Cr rectification order (Oct 1)
A major de-risking event. The Deputy Commissioner's GST notice for FY22-23 was significantly reversed on appeal. This removes a material contingency from the P&L and clears a regulatory overhang that had been weighing on sentiment.
2 · Promoter pledges 74% of stake (Sep, Aug) — liquidity signal?
Lunolux Midco (62.55% holder) disclosed pledging 62.55% + an additional 11.53% on Sep 22 and through Catalyst Trusteeship on Sep 18. The timing (post-ATH decline) and scale suggest either refinancing or covenant pressure, not conviction buying. Street will be watching for any margin calls or further encumbrances.
3 · ESG upgrade: CRISIL ESG score 58 → 62 (Sep 9)
Positive sentiment on sustainability; SES ESG also rated 63.4. Routine for a consumer-facing comapny, but supports long-term narrative on brand resilience and corporate governance.
4 · Institutional investor roadshow (Aug 24)
Pre-result engagement with FIIs/DIIs. FII ownership has drifted 0.41pp lower QoQ to 13.25%, and DII is steady at 6.70%; this suggests some FII caution but no panic exit.
The three things to watch on result day
1. Revenue growth acceleration or stall? Q1's 15.3% YoY was the highest ever per the disclosures. If Q2 slips to single digits (seasonal + market softness) or stays above 12% (momentum intact), that sets the tone for the full year. 2. Margin recovery to 12%+. Q1's 10.5% EBITDA margin was the real miss. Higher A&P spends and lower gross margin drove the slip. Management commentary on cost normalization and pricing power in water purifiers will be critical. 3. Water purifier mix and growth rate. At 7% household penetration, this is the runway. If electric purifier revenue is growing at 20%+ YoY and maintaining the 42-43% revenue mix, the long-term target of ₹5,400–5,600 Cr is plausible. Any deceleration or mix pressure signals the outer years may need repricing.
Eureka Forbes reports Q2 FY27 on November 2. The Street consensus is bullish (Strong Buy, ₹653.85 avg target), but sentiment has cooled sharply—the stock is down 54% from its ATH and trading on oversold RSI. This print is not a make-or-break moment, but it is a credibility test: can the company grow revenue in the mid-teens and recover operating leverage? Margin recovery to 12%+ EBITDA and sustained water purifier momentum are table stakes. Watch for any management commentary on FY27 full-year guidance, the roadmap to FY30 targets, and the impact of the recent GST relief on cash and reinvestment capacity.
Informational and educational content only. Not investment advice.